Effect of Tamsulosin in Preventing Ureteral Stent – Related Morbidity: A Prospective Study

Damiano, Rocco; Autorino, Riccardo; Sio, Marco De; Spiezia, Nicola; Palumbo, I.M.; D’Armiento, Massimo

doi:10.1016/s1569-9056(08)60147-5

Cited by 23 publications

(49 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Russian article published in Urologiia met the inclusion criteria according to the English abstract in PubMed; however it was subsequently excluded, since the full text could not be located (21). A total of 14 RCTs including 1,075 patients were included in the present meta-analysis (13,15,16,(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32).…”

Section: Resultsmentioning

confidence: 99%

“…Table I outlines the characteristics of each study included in the present meta-analysis. All included studies were RCTs; eight studies were performed in Asia, (24)(25)(26)(27)(28)31,32) three in Europe (13,16,22), two in Africa (15,29), and one in America (23). Participant ages ranged from 17-87 and the follow up periods were 1-6 weeks.…”

Section: Resultsmentioning

confidence: 99%

“…sub-scores, five trials (15,26,27,29,32) employed voiding symptoms sub-scores, and seven trials (13,16,(22)(23)(24)(25)30) evaluated USSQ urinary symptoms scores in order to evaluate the effectiveness of α 1 -adrenoceptor antagonists as therapeutic agents for patients with USS. VAPS was adopted in nine studies (13,15,16,23,25,26,28,30,32) and USSQ pain score was applied in six trials (13,16,(22)(23)(24)(25) In eight studies, analgesics and/or antibiotics were used in all patients as a general therapy.…”

Section: Resultsmentioning

confidence: 99%

“…VAPS was adopted in nine studies (13,15,16,23,25,26,28,30,32) and USSQ pain score was applied in six trials (13,16,(22)(23)(24)(25) In eight studies, analgesics and/or antibiotics were used in all patients as a general therapy. No significant differences in the rates of employment and sexual activity were demonstrated between the treatment groups.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

Zhang

Cheng

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The present meta-analysis aimed to evaluate the current evidence for the use of α 1 -blockers in relieving ureteric stent-related symptoms (USS). Electronic databases, including PubMed, Embase and Cochrane Library, were searched and two independent reviewers identified relevant parallel randomized controlled trials (RCTs), assessed trial quality and extracted data. Review Manager (version 5.2) was used to conduct a meta-analysis of the data. Significant advantages were demonstrated in the treatment group based on International Prostate Symptom Score (IPSS), voiding symptom sub-scores [mean difference (MD), -2.66; 95% confidence interval (CI), (-4.36, -0.96)], Ureteral Stent Symptom Questionnaire (USSQ) urinary symptoms score (MD, -5.84; 95%CI, -9.35 to -2.33), IPSS quality of life score (MD, -1.46; 95%CI, -2.64 to -0.28) USSQ quality of life score (MD, -0.69; 95%CI, -1.10 to -0.28), USSQ pain score (MD, -3.97; 95%CI, -5.52 to -2.42), Visual Analog Pain Scale (MD, -1.53; 95%CI, -2.25 to -0.80) and USSQ general health score (MD, -1.82; 95%CI, -2.47 to -1.18). No significant differences were detected from the following results: IPSS storage symptom sub-score (MD, -0.93; 95%CI, -2.28 to 0.43), USSQ sexual matters score (MD, -0.10; 95%CI, -0.79 to 0.59), USSQ work performance score (MD, 1.64; 95%CI, and USSQ additional problems score (MD, -2.02; 95%CI, -4.55 to 0.52). However, significant between-trial heterogeneity was detected following statistical analysis and there were insufficient data to trace its source. The existing RCT data supported the hypothesis that α 1 -blockers beneficially influence pain, urinary symptoms and the quality of life of patients with an indwelling ureteral stent.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

Zhang

Cheng

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…The routine use of alpha blockers not widely adopted and in our institution we used Tamsulosin sporadically as discharge medication [9]. Microscopic and mild gross haematuria are usually related to urothelial irritation and self-limited.…”

Section: Discussionmentioning

confidence: 99%

Part of the Solution and Part of the Problem-Report on the Ureteric Stent Use in a Tertiary Referral Center in Australia

Ilie¹,

Ilie²

2017

Med Surg Urol

View full text Add to dashboard Cite

show abstract

2236 the Effects of Tamsulosin, Solifenacin and Combination Therapy for the Treatment of Ureteral Stent Related Discomforts

Park¹,

Park²,

Kwon³

et al. 2011

Journal of Urology

View full text Add to dashboard Cite

Purpose:To evaluate the effect of tamsulosin, solifenacin, and combination therapy of two agents in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents. Materials and Methods: A total of 168 patients underwent placement of a double-J ureteral stent after retrograde ureteroscopy for urinary stone disease. All patients received polyurethane double-J ureteral stents (6 Fr, 24 or 26 cm), which were removed a mean of 14 days postoperatively. A total of 48 patients were given no medication (Group 1), 43 patients were given tamsulosin 0.2 mg once daily (Group 2), 45 patients were given solifenacin 5 mg once daily (Group 3), and 32 patients were given a combination of two agents postoperatively (Group 4). International Prostate Symptom Score/quality of life (IPSS/QoL) and visual analogue pain scale (VAPS) questionnaires were completed by each patient at 1 day postoperatively and on the day of stent removal. Results: In the total group of patients, the mean age was 50.24±12.90 years. There was a significant difference in the IPSS total score between group 1 and groups 3 and 4. Group 4 also differed significantly from group 1 in the irritative subscore. The obstructive subscore differed between groups 2 and 4 and group 1. There was a statistically significant difference between group 1 and group 4 in the QoL score. There were no significant differences in the VAPS. Conclusions: Combination therapy with tamsulosin and solifenacin improved both irritative and obstructive symptoms more than in the other groups. Combination therapy should be strongly considered for patients who complain of stent-related symptoms.

show abstract

Effect of Tamsulosin in Preventing Ureteral Stent – Related Morbidity: A Prospective Study

Cited by 23 publications

References 0 publications

α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

Part of the Solution and Part of the Problem-Report on the Ureteric Stent Use in a Tertiary Referral Center in Australia

2236 the Effects of Tamsulosin, Solifenacin and Combination Therapy for the Treatment of Ureteral Stent Related Discomforts

Contact Info

Product

Resources

About